ArticleOcular immunology and inflammation2022
Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?
Article in Ocular immunology and inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Rethinking phase III trials in retinal biosimilars: Do we still need them?Eye (London, England) · 2026Article
- Anti-vascular endothelial growth factors in retinal and choroidal diseases - Present landscape.Indian journal of ophthalmology · 2026Review
- Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events.Journal of clinical pharmacology · 2026Article
- Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature.Eye and vision (London, England) · 2024Article
- Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration.Japanese journal of ophthalmology · 2024Article
- Factors Associated With Intraocular Inflammation in Neovascular Age-Related Macular Degeneration Patients Treated With Brolucizumab.Investigative ophthalmology & visual science · 2024Observational
- Brolucizumab versus Aflibercept in Patients with Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.Scientific reports · 2022Article
- Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.BMC ophthalmology · 2022Article
- Bilateral blindness after uneventful brolucizumab injection for macular degeneration.BMC ophthalmology · 2022Article
- Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.